Abstract
Introduction Frailty is common in patients with atherosclerotic disease and is associated with substantially increased morbidity, mortality and significant economic and resource implications. Major limb amputation (MLA) secondary to critical limb threatening ischaemia (CLTI) is also associated with high mortality rates. This study aims to examine the association between frailty, as defined by the Rockwood Clinical Frailty Scale (CFS), on mortality rates in patients undergoing MLA for CLTI.
Methods This multi-centre, prospective observational cohort study will collect data on MLA performed for CLTI between November 2017 to December 2021 (North Bristol Trust) and January 2016 to October 2021 (NHS Greater Glasgow & Clyde). All patients undergoing MLA for CLTI will be included. Exclusion criteria are MLA for other aetiology, insufficient data to generate CFS score and minor lower limb amputations. Data collected includes age, sex, deprivation index and Charlson Comorbidity Index variables. A consultant/registrar with specialist-interest in frailty will allocate CFS scores based on pre-operative functional status. Three categories will be used: robust (CFS 1-3), mildly frail (CFS 4-5) and frail (CFS 6-8). CFS 9, ‘terminally ill’, will be presented separately. Primary outcome is all-cause mortality following MLA. Secondary outcome is length of stay. Sample size calculation assumed a mortality of 30% in robust and 40% in frail patients (HR=0.7) in a 1:2 ratio (robust:frail), calculating 1000 patients required, using a 0.05 significance level and 90% power. Outcome data will be analysed by multivariable Cox proportional baseline hazards regression controlling for demographic and operative variables (e.g., sex, age, deprivation index, comorbidity index, urgency of operation).
Discussion It is expected the study results will inform clinical decision-making and contribute toward an evidence pool which will inform service planning.
Study contributors
NBT vascular department – proving data on all patients that have undergone LLA in the last 5 years.
NHSGGC vascular department – proving data on all patients that have undergone LLA in the last 5 years.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any financial support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This quality improvement project has been registered with North Bristol Trust Quality Improvement Department (QI reference number: QI33977) and necessary Caldicott approval was granted prior to obtaining data from NHS Greater Glasgow & Clyde Research and Ethics department.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
RESEARCH REFERENCE NUMBERS, QI reference number: QI33977
Data Availability
Pseudonymised data will only be available to the chief investigator (Philip Braude) and the management group named on the protocol. In line with many peer-reviewed journal policies for data sharing, data sharing may be offered to third parties only on request to the study CI with review by the study sponsor to ensure legitimate academic interest. Data will be shared with anonymous records if deemed appropriate, arranged via data sharing agreement, and transferred using secure systems. If requests originate from outside the EU this will be discussed with the study sponsor.
